Key result
Recombinant human soluble thrombomodulin administration was associated with lower in-hospital all-cause mortality in patients with sepsis-induced DIC (OR 0.757; 95% CI 0.574-0.999; P=0.049).
Why the study?
Does recombinant human soluble thrombomodulin reduce in-hospital all-cause mortality in adult patients with sepsis-induced disseminated intravascular coagulation?
Population
1,784 adult patients diagnosed with sepsis-induced disseminated intravascular coagulation admitted to 42…
Comparison
Recombinant human soluble thrombomodulin (rhTM) vs Control group (no rhTM)
Design
Cohort
Follow-up
In-hospital
Authors
Loading...
rhTM use was associated with lower mortality in sepsis DIC; leaves open whether RCTs will confirm benefit before practice change.
Cohort (n=1,784)
Yes
Does recombinant human soluble thrombomodulin reduce in-hospital all-cause mortality in adult patients with sepsis-induced disseminated intravascular coagulation?
Odds Ratio: 0.757 (95% CI 0.574–0.999)
p-value: p=0.049
Recombinant human soluble thrombomodulin administration is associated with reduced in-hospital all-cause mortality in critically ill patients with sepsis-induced DIC.
Yamakawa et al. (2016) conducted a cohort in Sepsis-induced disseminated intravascular coagulation (n=1,784). Recombinant human soluble thrombomodulin vs. Control (no rhTM) was evaluated on In-hospital all-cause mortality (OR 0.757, 95% CI 0.574-0.999, p=0.049). Recombinant human soluble thrombomodulin administration was associated with lower in-hospital all-cause mortality in patients with sepsis-induced DIC (OR 0.757; 95% CI 0.574-0.999; P=0.049).
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: